J. Chouitar

Most-cited papers

1. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.

   Akito Nakamura, T. Arita, S. Tsuchiya, J. Donelan +6 more

   2013Cancer Research105 citations Open access

   Semantic Scholar

   Save

2. Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.

   A. Gould, Ruth Adams, S. Adhikari, K. Aertgeerts +44 more

   2011Journal of Medicinal Chemistry34 citations Open access

   Semantic Scholar

   Save

3. Discovery and optimization of pyrazolopyrimidine sulfamates as ATG7 inhibitors.

   Shih-Chung Huang, S. Adhikari, J. Brownell, Emily F. Calderwood +13 more

   2020Bioorganic & Medicinal Chemistry27 citations Open access

   Semantic Scholar

   Save

4. Optimization of tetrahydronaphthalene inhibitors of Raf with selectivity over hERG.

   Shih-Chung Huang, S. Adhikari, Roushan Afroze, K. Brewer +17 more

   2016Bioorganic & Medicinal Chemistry Letters8 citations Open access

   Semantic Scholar

   Save

5. A Sensitive IHC Method for Monitoring Autophagy-Specific Markers in Human Tumor Xenografts

   Helen He, Yu Yang, Zhongmin Xiang, Lun-Yin Yu +9 more

   2016Journal of Biomarkers7 citations Open access

   Semantic Scholar

   Save

6. Abstract C146: Combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 inhibits the growth of BRAF mutant and RAS mutant preclinical models of melanoma and CRC.

   E. Cunniff, Julie Zhang, J. Chouitar, J. Mettetal +16 more

   20134 citations

   Semantic Scholar

   Save

7. Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models of melanoma and CRC.

   E. Cunniff, Julie Zhang, J. Chouitar, J. Mettetal +16 more

   20132 citations

   Semantic Scholar

   Save

8. Abstract 2908: A sensitive immunohistochemistry method forin vivoautophagy biomarker detection and pharmacodynamic studies

   Yu Yang, N. D’Amore, J. Chouitar, Jie Yu +10 more

   20150 citations

   Semantic Scholar

   Save

9. Abstract 4247: Characterization of the selective pan-RAF inhibitor TAK-632 with antitumor activity in BRAF inhibitor-resistant melanoma

   Akito Nakamura, T. Arita, S. Tsuchiya, J. Donelan +6 more

   20140 citations

   Semantic Scholar

   Save

10. 493 Preclinical pharmacokinetic (PK)/pharmacodynamic (PD)/Efficacy modeling for MLN2480, an investigational pan-RAF kinase inhibitor, in A375 and SKMEL-2 human melanoma xenografts

    M. Patel, J. Chouitar, J. Mettetal, E. Gangolli +6 more

    20140 citations

    Semantic Scholar

    Save

11. Abstract A215: Integrated analysis of clinical pharmacokinetics (PK), nonclinical PK/efficacy (E) and pharmacodynamic (PD)/E relationships, and translational PK/PD simulations to guide clinical dose and schedule of MLN2480, an oral investigational pan-RAF kinase inhibitor.

    S. Faucette, J. Mettetal, Xiao-Fei Zhou, J. Chouitar +5 more

    20130 citations

    Semantic Scholar

    Save